6451-50-9

Usage

Type

Derivative of sulfonamide

Usage

Intermediate in the synthesis of pharmaceuticals, dyes, and other organic compounds

Potential applications

Treatment of various medical conditions (e.g. cancer, infectious diseases), corrosion inhibitor in industrial applications

Chemical structure

Amino group at the 2-position, methoxy group at the 5-position, and benzene ring with a sulphonamide group attached

Properties

Versatile building block for the development of novel therapeutic agents

Upstream product

• 104-94-9 4-methoxy-aniline 
• 71254-67-6 7-methoxy-3-oxo-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide 

Downstream Products

• 549495-11-6 3-Methyl-3,4-dihydro-2H-1,2,4-benzothiadiazin-7-ol 1,1-Dioxide 
• 1432503-63-3 C₁₇H₁₅F₃N₂O₅S 
• 1432503-62-2 C₁₇H₁₆BrFN₂O₅S 
• 1432503-61-1 methyl 2-(7-methoxy-1,1-dioxo-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-59-7 methyl 2-(2-(4-bromo-2-fluorobenzyl)-7-methoxy-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1204575-07-4 2-(cyclopropylamino)-5-methoxybenzenesulfonamide 
• 1161945-12-5 2-(2,3-dichloro-benzenesulfonylamino)-5-methoxy-benzenesulfonamide 
• 1161944-99-5 2-[2-(4-chloro-phenyl)-ethanesulfonylamino]-5-methoxy-benzenesulfonamide 
• 1044277-15-7 2-benzyl-5-hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-6-pyrrolidin-1-yl-2H-pyridazin-3-one 
• 477932-78-8 N-(4-methoxy-2-sulfamoylphenyl)malonamic acid ethyl ester 

Relevant academic research and scientific papers

FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY

A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

Radiosynthesis of a carbon-11-labeled AMPAR allosteric modulator as a new PET radioligand candidate for imaging of Alzheimer's disease

To develop PET tracers for imaging of Alzheimer's disease, a new carbon-11-labeled AMPAR allosteric modulator 4-cyclopropyl-7-(3-[11C]methoxyphenoxy)-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide ([11C]8) has been synthesized

Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase

The development and progression of chronic complications in diabetic patients, such as retinopathy, nephropathy, neuropathy, cataracts, and stroke, are related to the activation and/or overexpression of aldose reductase (ALR2), which is a member of the al

Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase

The synthesis and optimisation of HCV NS5B polymerase inhibitors with improved potency versus the existing compound 1 is described. Substitution in the benzothiadiazine portion of the molecule, furnishing improvement in potency in the high protein Replicon assay, is highlighted, culminating in the discovery of 12h, a highly potent oxyacetamide derivative.

PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS

The invention is directed to pyrro[l,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

PYRIDAZINONE COMPOUNDS

The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

Inhibitors of HCV NS5B polymerase: Synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring

A series of non-nucleoside HCV NS5B polymerase inhibitors based on the N-1-benzyl or N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine core substituted in the D-ring aromatic moiety have been prepared and evaluated. Aromatic substituents extending from position 7 of the D-ring exhibited excellent potency against both genotypes 1a and 1b.

PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

Anti-infective agents

Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

Anti-infective agents

Compounds having the formula are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.